GeneOne specializes in nucleic-acid based treatments
and novel small-molecule therapeutics
Our DNA plasmid technology enables in vivo expression of recombinant proteins and monoclonal antibodies as therapeutic agents.
The target-specific gene inserts we design are optimized for stable expression within human cells. Each gene insert is carried within a DNA plasmid vector that has a long safety record and is the same DNA plasmid vector used for our DNA vaccines.
Naked DNA is non-immunogenic and numerous investigators have published that DNA does not integrate into the genome. In contrast, viral vectored vaccines and products have potential safety concerns, especially for immunosuppressed patients, and may not allow repeat courses of treatment due to an immune response against the viral vector.
DNA plasmid-mediated delivery of antibodies or recombinant proteins allows for in vivo production of these therapeutic molecules which obviates the need for the elaborate and costly manufacturing processes currently used to make them.
GLS-5100 Prevention of herpes zoster (shingles)
GLS-5140 Prevention of severe fever with thrombocytopenia syndrome (SFTS)
Prevention of Middle East respiratory syndrome coronavirus (MERS-CoV) infection
GLS-5700 Prevention of Zika virus infection
GLS-6100/GLS-6150 Prevention of hepatitis C
GLS-3000(mRNA) Prevention of COVID-19 disease
GLS-5310(DNA) Prevention of COVID-19 disease
GLS-5310(DNA) Prevention of coronavirus disease 2019 (COVID-19)
GLS-7000 HER2-targeted mAb Drug Resistant Breast Cancer
GLS-7100 Hemophilia A
GLS-8000 Prevention of Chronic Hepatitis B/Hepatitis B
GLS-8100 Rheumatoid Arthritis
GLS-1027 Acute ischemic nephritis
GLS-1027 COVID-19 Pneumonitis
GLS-1200 Chronic Rhinosinusitis
GLS-1200 COVID-19 Prophylaxis
GLS-1200 Influenza and Common cold viruses